KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Income from Continuing Operations fell 289.96% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 16011.92%. This contributed to the annual value of -$4.8 million for FY2024, which is 9773.98% up from last year.
  • Per Esperion Therapeutics' latest filing, its Income from Continuing Operations stood at -$32.0 million for Q3 2025, which was down 289.96% from -$13.4 million recorded in Q2 2025.
  • Esperion Therapeutics' Income from Continuing Operations' 5-year high stood at $58.2 million during Q1 2024, with a 5-year trough of -$90.9 million in Q1 2021.
  • Its 5-year average for Income from Continuing Operations is -$42.9 million, with a median of -$51.6 million in 2023.
  • Per our database at Business Quant, Esperion Therapeutics' Income from Continuing Operations surged by 19246.41% in 2024 and then tumbled by 17129.71% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Income from Continuing Operations stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then plummeted by 53.58% to -$32.0 million in 2025.
  • Its Income from Continuing Operations stands at -$32.0 million for Q3 2025, versus -$13.4 million for Q2 2025 and -$41.5 million for Q1 2025.